Search research articles
Contact Us
Filters
Showing results (181-190 of 216) with videos related to
Page
of 22
Sort By:
Diabetes Care
|
October 1, 1994
Combined analysis of islet cell antibodies that cross-react with mouse pancreas, antibodies to the M(r) 64,000 islet protein, and antibodies to glutamate decarboxylase in type I diabetic patients
L Chaillous, M Delamaire, L Martignat, et al.
Diabetes Care
|
February 1, 1991
Telematic transmission of computerized blood glucose profiles for IDDM patients
A Billiard, V Rohmer, M A Roques, et al.
International Journal of Obesity (2005)
|
May 5, 2011
Dietary fat intake and polymorphisms at the PPARG locus modulate BMI and type 2 diabetes risk in the D.E.S.I.R. prospective study
A Lamri, C Abi Khalil, R Jaziri, et al.
Diabetes Research and Clinical Practice
|
April 11, 2017
The impact of level of education on vascular events and mortality in patients with type 2 diabetes mellitus: Results from the ADVANCE study
J I Blomster, S Zoungas, M Woodward, et al.
Kidney International
|
April 12, 2000
Association between high von willebrand factor levels and the Thr789Ala vWF gene polymorphism but not with nephropathy in type I diabetes. The GENEDIAB Study Group and the DESIR Study Group
C Lacquemant, C Gaucher, C Delorme, et al.
Diabetes Care
|
June 22, 2000
Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR Study in Western Europe and North Africa
M Marre, M Lièvre, D Vasmant, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
March 26, 2009
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M Marre, J Shaw, M Brändle, et al.
Diabetes Research and Clinical Practice
|
June 15, 2010
The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial
S Zoungas, J Chalmers, A P Kengne, et al.
Diabetes, Obesity & Metabolism
|
May 17, 2013
The influence of physical activity on vascular complications and mortality in patients with type 2 diabetes mellitus
J I Blomster, C K Chow, S Zoungas, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 1, 2001
Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse
W Huang, Y Gallois, N Bouby, et al.
Page
of 22
Search research articles
Search
Showing results (181-190 of 216) with videos related to
Sort By:
Page
of 22
Diabetes Care
|
October 1, 1994
Combined analysis of islet cell antibodies that cross-react with mouse pancreas, antibodies to the M(r) 64,000 islet protein, and antibodies to glutamate decarboxylase in type I diabetic patients
L Chaillous, M Delamaire, L Martignat, et al.
Diabetes Care
|
February 1, 1991
Telematic transmission of computerized blood glucose profiles for IDDM patients
A Billiard, V Rohmer, M A Roques, et al.
International Journal of Obesity (2005)
|
May 5, 2011
Dietary fat intake and polymorphisms at the PPARG locus modulate BMI and type 2 diabetes risk in the D.E.S.I.R. prospective study
A Lamri, C Abi Khalil, R Jaziri, et al.
Diabetes Research and Clinical Practice
|
April 11, 2017
The impact of level of education on vascular events and mortality in patients with type 2 diabetes mellitus: Results from the ADVANCE study
J I Blomster, S Zoungas, M Woodward, et al.
Kidney International
|
April 12, 2000
Association between high von willebrand factor levels and the Thr789Ala vWF gene polymorphism but not with nephropathy in type I diabetes. The GENEDIAB Study Group and the DESIR Study Group
C Lacquemant, C Gaucher, C Delorme, et al.
Diabetes Care
|
June 22, 2000
Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR Study in Western Europe and North Africa
M Marre, M Lièvre, D Vasmant, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
March 26, 2009
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M Marre, J Shaw, M Brändle, et al.
Diabetes Research and Clinical Practice
|
June 15, 2010
The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial
S Zoungas, J Chalmers, A P Kengne, et al.
Diabetes, Obesity & Metabolism
|
May 17, 2013
The influence of physical activity on vascular complications and mortality in patients with type 2 diabetes mellitus
J I Blomster, C K Chow, S Zoungas, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 1, 2001
Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse
W Huang, Y Gallois, N Bouby, et al.
Page
of 22